Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 and VG2025 in advanced colorectal cancer with liver metastases
NCT07357220Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of VG2025 in colorectal cancer (CRC), sponsored by Akeso, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
VG2025
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07357220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357220.